IW 389

August 6, 2026 Viktor Zarev 0 min read
  1. Eli Lilly beats expectations in spite of GLP-1 weakness. 
  2. AI bots help people sign up for Medicaid. 
  3. Could AI-based automation close healthcare’s workforce gap?
  4. U.S. men aren’t getting MRI scans for prostate cancer workup. 
  5. Bioengineered chewing gum could prevent head and neck cancer.
  6. FIT-based screening reduces colon cancer rates. 
  7. Hospitals could get windfall for treating low-income patients.
  8. Portable blood test device supports remote health monitoring.
  9. Moderna starts trial of vaccine against Ebola strain. 
  10. Virginia sees first locally acquired dengue fever case.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions August 13, 2026

More Interventional Cardiologists, More Low-Value Stents August 13, 2026

The old adage that "built capacity gets used" applies to cardiology too. A Lown Institute study found that regions with the most PCI-performing physicians lead to a disproportionately higher share of patients receiving stents they’re unlikely to benefit from.

Cardiology Business August 10, 2026

iRhythm Expands MCT Footprint with VitalConnect Acquisition August 10, 2026

iRhythm, best known for its Zio cardiac monitoring wearables, is moving to expand well beyond its 14-day-patch roots by acquiring wearable biosensor company VitalConnect for $287.5M.

Cardiology Pharmaceuticals August 6, 2026

ZEUS Tells Us Inflammation Might Not Be the Answer August 6, 2026

Cardiovascular inflammation has been the talk of the town in cardiology, and while Novo Nordisk was wise to pursue treating it, results from the ZEUS trial have led to a thunderous debate on whether or not it ever played a role in ASCVD.